Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Shanming Wu"'
Autor:
Jinlin Hou, Qin Ning, Zhongping Duan, Yu Chen, Qing Xie, Lunli Zhang, Shanming Wu, Hong Tang, Jun Li, Feng Lin, Yongfeng Yang, Guozhong Gong, Yanwen Luo, Shelley Xie, Hongyuan Wang, Mateo, Roberto, Yazdi, Tahmineh, Abramov, Frida, Yee, Leland J., Flaherty, John
Publikováno v:
Journal of Clinical & Translational Hepatology; May2024, Vol. 12 Issue 5, p469-480, 12p
Autor:
Zujiang Yu, Zhong-Nan Xu, Xiaofan Chen, Yanyan Yu, Jia Shang, Jing-Hang Xu, Jun Li, Ling Wang, Jun Cheng, Wenhong Zhang, Hao Wang, Chong-Wen Si, Xinyue Chen, Zhiliang Gao, Qing Mao, Hong Tang, Shanming Wu, Qing Xie, Wei Zhao, Jun Dai, Yanan Fan
Publikováno v:
World Journal of Clinical Cases
BACKGROUND Tenofovir disoproxil fumarate (TDF) is a prodrug of a nucleotide analogue. As an antiviral drug, TDF has been proposed in the first-line treatment of chronic hepatitis B (CHB). Qingzhong, a brand name of TDF, commercialized by Jiangsu Chia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::692c42f02a46b6f073e47b4712077083
https://doi.org/10.12998/wjcc.v9.i18.4690
https://doi.org/10.12998/wjcc.v9.i18.4690
Autor:
Zhiliang Gao, Chen Pan, Shanming Wu, Hao Wang, Wenyan Zhang, Jinlin Hou, Cui Xiong, Xin-Xin Zhang, Qing Mao, Xieer Liang, Hong Tang, Jun Li, Yimin Mao, Qin Ning, Hong Ren, Jun Cheng, Junqi Niu, Chengwei Chen, Jiming Zhang, Wei Zhao, Qing Xie, Deming Tan, Jidong Jia, Jifang Sheng, Min Xu, Shijun Chen
Publikováno v:
Hepatology International
Background and aim Long-term treatment with tenofovir disoproxil fumarate (TDF) has demonstrated suppression of viral replication outside of China. This study aims to assess efficacy, resistance and safety of TDF for up to 240 weeks in Chinese patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d6c7a4f75f7e062e7a4c6cf5927a1ef
https://doi.org/10.1007/s12072-019-09943-6
https://doi.org/10.1007/s12072-019-09943-6
Autor:
Jin Lin Hou, Feng Lin, Lai Wei, Luisa M. Stamm, Yanhang Gao, Qin Ning, Seng Gee Lim, Sophia Lu, Peng Hu, Jidong Jia, Kinh Nguyen Van, Zhuangbo Mou, Abhasnee Sobhonslidsuk, Ming Xu, Teerha Piratvisuth, Minghua Su, Hoi Poh Tee, Guozhong Gong, Satawat Thongsawat, Guiqiang Wang, Lunli Zhang, Rosmawati Mohamed, Shanming Wu, Zhi Liang Gao, Jia Shang, Hongmei Mo, Hung Le Manh, Jun Cheng, Diana M. Brainard, Qing Xie, Yongfeng Yang, Long Dao, Xiaguang Dou, Hadas Dvory-Sobol, Zhongping Duan, Thi Tuyet Phuong Le, Pisit Tangkijvanich, Yan Huang, Hong Tang, Tawesak Tanwandee, Jun Li, Yuemin Nan, Yimin Mao, Chee-Kiat Tan
Publikováno v:
The Lancet Gastroenterology & Hepatology. 4:127-134
Summary Background Treatment with combined sofosbuvir and velpatasvir has resulted in high sustained virological response rates in patients chronically infected with hepatitis C virus (HCV) with genotypes 1–6 in clinical trials and real-world setti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16deead8947d036b7f65eab87a163c5d
https://doi.org/10.1016/s2468-1253(18)30343-1
https://doi.org/10.1016/s2468-1253(18)30343-1
Autor:
Jun Cheng, Hong Tang, Lai Wei, Qin Ning, Shanming Wu, Jin Lin Hou, Gregory Camus, Diana M. Brainard, Qing Xie, Brian McNabb, Jidong Jia, Yuemin Nan, Peng Hu, Guozhong Gong, Guiqiang Wang, Jianning Jiang, Fangqiu Zhang, Zhuangbo Mou, Jun Li, Zhongping Duan, Anu Osinusi, Yanhang Gao, Lunli Zhang, Hongmei Mo
Publikováno v:
Hepatology International
Background Chronic hepatitis C virus (HCV) infection is a significant medical burden in China, affecting more than 10 million persons. In clinical trials and real-world settings, treatment with ledipasvir/sofosbuvir in patients with genotype 1 HCV in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31bf2cddb23e441b93b874b2aa0f116c
http://europepmc.org/articles/PMC5904238
http://europepmc.org/articles/PMC5904238
Autor:
Zhuangbo Mou, Jun Li, Qin Ning, Jun Qi Niu, Deyuan Jiang, Steven J. Knox, Shanming Wu, Polina German, Jianning Jiang, Wu Li, Yuemin Nan, Zhi Liang Gao, Zhongping Duan, Guiqiang Wang, Kathryn Kersey, Jin Lin Hou, Lun Li Zhang, Jenny C. Yang, Yongfeng Yang, Benedetta Massetto, Hong Tang, Lai Wei, Jun Cheng, Feng Lin, Peng Hu, Xiaoguang Dou, Min Xu, Qing Xie, Diana M. Brainard, Guozhong Gong, Jidong Jia, Lanjuan Li, Hongmei Mo, Jiaji Jiang
Publikováno v:
Journal of Gastroenterology and Hepatology. 33:1168-1176
BACKGROUND AND AIM Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase with pangenotypic potency. This phase 3b study evaluated the safety and efficacy of sofosbuvir + ribavirin ± peginterferon in Chinese p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64dfe8967a57a556adf872ff56712514
https://doi.org/10.1111/jgh.14102
https://doi.org/10.1111/jgh.14102
Autor:
Jidong Jia, Chengwei Chen, Jinlin Hou, Fu-Sheng Wang, Gs-Us, Qing Xie, Hong Tang, Jun Li, Anuj Gaggar, Feng Lin, John F. Flaherty, Qin Ning, Shuyuan Mo, Cong Cheng, Guozhong Gong, Shanming Wu, Gs-Us China Investigators, Gregory Camus, You Chen, Zhongping Duan, Yan Huang, Yongfeng Yang, Mingxiang Zhang, Lunli Zhang
Publikováno v:
Journal of Clinical and Translational Hepatology
Background and Aims Tenofovir alafenamide (TAF) has similar efficacy to tenofovir disoproxil fumarate (TDF) but with improved renal and bone safety in chronic hepatitis B patients studied outside of China. We report 3-year results from two phase 3 st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89f17c8913c79907c14a72607663af6d
https://doi.org/10.14218/jcth.2020.00145
https://doi.org/10.14218/jcth.2020.00145
Autor:
Qing Xie, Jun Cheng, Qin Ning, Tawesak Tanwandee, Hoi Poh Tee, Seng Gee Lim, Zhuangbo Mou, Abhasnee Sobhonslidsuk, Ming Xu, Jun Li, Yuemin Nan, Zhi Liang Gao, Yongfeng Yang, Hong Tang, Jin Lin Hou, Guiqiang Wang, Teerha Piratvisuth, Guozhong Gong, Minghua Su, Sophia Lu, Shanming Wu, Thi Tuyet Phuong Le, Yimin Mao, Chee-Kiat Tan, Hadas Dvory-Sobol, Hung Le Manh, Yan Huang, Yanhang Gao, Rosmawati Mohamed, Lai Wei, Jia Shang, L.M. Stamm, Kinh Nguyen Van, Pisit Tangkijvanich, Lunli Zhang, Hongmei Mo, Xiaguang Dou, Zhongping Duan, Long Dao, Peng Hu, Satawat Thongsawat, Diana M. Brainard, Jidong Jia, Feng Lin
Publikováno v:
SSRN Electronic Journal.
Background: Treatment with sofosbuvir/velpatasvir has resulted in high sustained virologic response rates in HCV-infected patients with genotype 1 to 6 in clinical trials and real-world settings, but its efficacy and safety has not been assessed in A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f527a9514bec88f483757a2c974f15f
https://doi.org/10.2139/ssrn.3255830
https://doi.org/10.2139/ssrn.3255830
Autor:
Lai, Wei, Qing, Xie, Jin Lin, Hou, Jidong, Jia, Wu, Li, Min, Xu, Jun, Li, Shanming, Wu, Jun, Cheng, Jianning, Jiang, Guiqiang, Wang, Yongfeng, Yang, Zhuangbo, Mou, Zhi Liang, Gao, Guozhong, Gong, Jun Qi, Niu, Peng, Hu, Hong, Tang, Feng, Lin, Xiaoguang, Dou, Lanjuan, Li, Lun Li, Zhang, Yuemin, Nan, Benedetta, Massetto, Jenny C, Yang, Steven J, Knox, Kathryn, Kersey, Polina, German, Hongmei, Mo, Deyuan, Jiang, Diana M, Brainard, Jiaji, Jiang, Qin, Ning, Zhongping, Duan
Publikováno v:
Journal of gastroenterology and hepatology. 33(6)
Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase with pangenotypic potency. This phase 3b study evaluated the safety and efficacy of sofosbuvir + ribavirin ± peginterferon in Chinese patients infected wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c375ff7c483472b6199695e64f30c1ad
https://pubmed.ncbi.nlm.nih.gov/29998515
https://pubmed.ncbi.nlm.nih.gov/29998515
Autor:
Qing Xie, Zujiang Yu, Zhong-Nan Xu, Xinyue Chen, Hong Tang, Hao Wang, Yanyan Yu, Wei Zhao, Jun Cheng, Jing-Hang Xu, Jun Li, Rongyue Liang, Chong-Wen Si, Jia Shang, Ling Wang, Qing Mao, Sa Wang, Zhiliang Gao, Shanming Wu, Jun Dai, Wenhong Zhang
Publikováno v:
Medicine. 98:e16778
Background:Tenofovir disoproxil fumarate (TDF) has been widely recommended as a first-line antiviral agent to treat chronic hepatitis B (CHB). Qingzhong and Viread, formulations of TDF commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e549c4b85e9371b1ddcc471c2571371
https://doi.org/10.1097/md.0000000000016778
https://doi.org/10.1097/md.0000000000016778